alexa Abstract | Efficacy of Low Dose Tenecteplase in Restoring Vessel Patency in a Clinically Relevant Large Animal Experimental Model

Journal of Research and Development
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Review Article Open Access


Background: We tested whether tenecteplase, a recombinant fibrin-specific plasminogen activator can induce efficient thrombolysis in lower doses than the hitherto indicated, compared to full-dose therapy for vessel thrombosis. Methods: Farm pigs (30-35 kg, n=23) were imposed in a clinically relevant model of common carotid-arteries (CA) and the left-anterior-descending (LAD) artery below the first diagonal occlusion. The vessels were initially externally injured followed by an appropriate for the vessel dose of thrombin. Occlusion was achieved in 80% for the LAD and 57% for the CA. Post occlusion the animals were allocated to one of the following groups: Group A) halfdose tenecteplase (2000IU); Group B) Full dose tenecteplase (5000IU); Group C) saline only. All animals received heparin and antiplatelet agents. The animals were followed-up for 120 minutes. Results: Sixty minutes after thrombolysis recanalization occurred in 58% of the occluded arteries in Group A, in 85% in Group B and in 20% in Group C (P=0.028). Both tenecteplase regimens were effective for treating CA thrombosis (71% Group A vs 75% in Group B vs 33% in Group C, P=0.286), but low dose was significantly less effective in reestablishing flow in LADs (25% in Group A vs 100% in Group B vs 0% in Group C, P=0.015). Vessel patency was sustained for at least 1hr. In Group A, flow velocity in LAD reached 30% of the baseline value and 45% in carotids, while in Group B flow was 160% and 55% respectively. No differences in hemodynamic tested parameters and in post reperfusion arrhythmias were observed between the groups. Conclusions: We developed a clinically relevant model useful for testing the efficacy of different thrombolytic regimens. Our data demonstrate that low dose tenecteplase can be successfully used for treating thrombosis of larger diameter vessels, such as the carotids, but appears inadequate for treating LAD thrombotic occlusions.

To read the full article Peer-reviewed Article PDF image | Peer-reviewed Full Article image

Author(s): Tseliou E, Ntalianis A, Diakos N, Pozios H, Repasos V, Katsaros F, Dimopoulos S, Kontopidi V, Margari Z and Nanas JN


Thrombolytics, Vessel thrombosis, Preclinical models, Research and Development

Share This Page

Additional Info

Loading Please wait..
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version